Immunovant IMVT
NASDAQ IMVT
$34.00 +0.35 (+1.04%)
As of: Oct 2, 2026 · 10:49 AM EDT

Immunovant (IMVT) Long-Term Investments (2019)

Updated

Immunovant (IMVT) recorded Long-Term Investments of $116.02 million in fiscal Q2 2020 (quarter ended Sep 30, 2019), up 0.6% from the prior quarter.

Analysis

Immunovant (IMVT) Long-Term Investments (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 266.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.22 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 69.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 2.62 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 1.56 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 5.79 Bn
10 Immunovant 6.97 Bn 6.97 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 116.02 Mn
Jun 30, 2019 115.34 Mn
API Access

Immunovant Long-Term Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-investments&ticker=IMVT&period=max&api_key=YOUR_API_KEY